论文部分内容阅读
消化系统疾病的诊断手段虽有许多进步,至今胰腺癌的早期诊断仍有困难。利用肿瘤标志作为临床诊断、筛选和随访已越来越广泛。早在1848年英国内科医生Henry Bence Jones首次报告多发性骨髓瘤患者尿中出现Bence-Jones蛋白,直到1978年7月29日英国医学杂志才开始使用肿瘤标志(Tumour Marker)这一术语。现在应用最广的肿瘤标志有甲胎蛋白、癌胚抗原(CEA)等,为许多肿瘤的诊断、疗效观察及术后随访提供了有力的辅助手段。单克隆抗体技术
Although there have been many advances in the diagnosis of digestive diseases, the early diagnosis of pancreatic cancer is still difficult. The use of tumor markers for clinical diagnosis, screening and follow-up has become more and more widespread. As early as 1848, British physician Henry Bence Jones first reported on the presence of Bence-Jones protein in the urine of patients with multiple myeloma, until the British Medical Journal began using the term Tumour Marker on July 29, 1978. At present, the most widely used tumor markers are alpha fetoprotein and carcinoembryonic antigen (CEA), which provide powerful aids for the diagnosis, efficacy observation, and follow-up of many tumors. Monoclonal antibody technology